WASHINGTON (AP) -- Federal health officials have approved the first lower-cost copy of a biotech drug in the U.S., a long-awaited milestone that could save billions for insurers, doctors and patients.
CHICAGO (AP) -- New drugs are making a dent against some hard-to-treat cancers, but some results raise fresh questions about whether the benefit is worth the cost.
Shares of Bristol-Myers Squibb Inc. and Merck & Co. gained about 4 percent each after the drugmakers announced encouraging results on experimental cancer medicines over the weekend.
Federal regulators said Tuesday that they've approved new suppliers for two crucial cancer drugs, easing critical shortages -- at least for the time being -- that have patients worried about missing life-saving treatments.